Nootropil réduit la durée du nystagmus vestibulaire.
Ingrédient actif: Piracetam
Disponibilité: disponible (25 packs)
Nootropil 800mg
Nom du produitPour la piluleÉconomisezPar paquetCommande
30 pilules€0.99€29.74Aujouter au panier
60 pilules€0.90€5.19€59.48 €54.29Aujouter au panier
90 pilules€0.88€10.38€89.22 €78.84Aujouter au panier
120 pilules€0.86€15.57€118.95 €103.38Aujouter au panier
180 pilules€0.85€25.95€178.43 €152.48Aujouter au panier
270 pilules€0.84€41.53€267.65 €226.12Aujouter au panier
360 pilules€0.83€57.10€356.87 €299.77Aujouter au panier

    NOOTROPIL is indicated for patients suffering from myoclonus of cortical origin, irrespective of aetiology, and should be used in combination with other anti-myoclonic therapies.


    Adults :

    The dosage regime shows important interindividual variability, requiring an individualised dose finding approach. A reasonable protocol would be to introduce piracetam at a dosage of 7.2 g/day, increasing by 4.8 g/day every 3 to 4 days up to a maximum of 20g/day, given in either 2 or 3 divided doses while keeping other antimyoclonic drugs unchanged at their optimal dosage. If possible, depending on clinical benefit, an attempt should be made to subsequently reduce the dosage of other antimyoclonic drugs.


    Take the medicine as prescribed by your doctor.


    Store this medicine at room temperature in a tightly-closed container, away from heat and light.


     Active ingredient: Piracetam


    NOOTROPIL (Piracetam) is contra-indicated in patients with severe renal impairment (renal creatinine clearance of less than 20 ml per minute), hepatic impairment and to those under 16 years of age. It is also contraindicated in patients with cerebral haemorrhage, Huntington's Chorea and in those with hypersensitivity to piracetam, other pyrrolidone derivatives or any of the excipients .

    More Information

    Nootropil should not be prescribed during pregnancy or when breastfeeding.


    The side effects reported in connection with Nootropil include nervousness, agitation, irritability, anxiety and sleep disturbances. The incidence of these during clinical trials was 5% or less and they were more often noted in the older patients taking more than 2.4 g daily. In the majority of cases a dose reduction sufficed to make these symptoms disappeared. Some patients may complain of fatigue or drowsiness. Gastro-intestinal problems such as nausea, vomiting, diarrhoea and stomachache have also been reported, but their Incidence during clinical trials was 2% or less. Other symptoms, such as vertigo, headaches, trembling and sexual stimulation have occasionally been reported.